Search Results
Institute of Biomedicine, Departments of Pathology, Otorhinolaryngology, Developmental Biology, University of Helsinki, Biomedicum, Haartmaninkatu 8, PL 63, Helsinki 00014 HY, Finland
Search for other papers by V Häyry in
Google Scholar
PubMed
Search for other papers by K Salmenkivi in
Google Scholar
PubMed
Search for other papers by J Arola in
Google Scholar
PubMed
Search for other papers by P Heikkilä in
Google Scholar
PubMed
Search for other papers by C Haglund in
Google Scholar
PubMed
Institute of Biomedicine, Departments of Pathology, Otorhinolaryngology, Developmental Biology, University of Helsinki, Biomedicum, Haartmaninkatu 8, PL 63, Helsinki 00014 HY, Finland
Search for other papers by H Sariola in
Google Scholar
PubMed
Introduction Phaeochromocytoma is a rare tumour of the adrenal medulla. We lack exact incidence figures in Finland, but in Sweden, the incidence is 2.1 per million ( Stenstrom & Svardsudd 1986 ). It usually arises from adrenergic cells in the
Institute of Clinical Chemistry and Laboratory Medicine, Department of Medicine, Reproductive and Adult Endocrinology Program, Urologic Oncology Branch, Department of Clinical Pathophysiology, Department of Clinical Physiology, Department of Laboratory Medicine and Pathology, Endocrinology, Internal Medicine, University of Dresden, 01307 Dresden, Germany
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Search for other papers by Thanh-Truc Huynh in
Google Scholar
PubMed
Search for other papers by Nan Qin in
Google Scholar
PubMed
Search for other papers by Gennady Bratslavsky in
Google Scholar
PubMed
Search for other papers by W Marston Linehan in
Google Scholar
PubMed
Search for other papers by Massimo Mannelli in
Google Scholar
PubMed
Search for other papers by Peter Friberg in
Google Scholar
PubMed
Search for other papers by Stefan K Grebe in
Google Scholar
PubMed
Search for other papers by Henri J Timmers in
Google Scholar
PubMed
Search for other papers by Stefan R Bornstein in
Google Scholar
PubMed
Institute of Clinical Chemistry and Laboratory Medicine, Department of Medicine, Reproductive and Adult Endocrinology Program, Urologic Oncology Branch, Department of Clinical Pathophysiology, Department of Clinical Physiology, Department of Laboratory Medicine and Pathology, Endocrinology, Internal Medicine, University of Dresden, 01307 Dresden, Germany
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Introduction Phaeochromocytomas and paragangliomas (PPGLs) are heterogeneous tumours with highly variable signs and symptoms and diverse clinical presentations ( Manger 2009 ). Much of the heterogeneity is due to wide-ranging variations in the types
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Dewi Astuti in
Google Scholar
PubMed
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Christopher J Ricketts in
Google Scholar
PubMed
Search for other papers by Rasheduzzaman Chowdhury in
Google Scholar
PubMed
Search for other papers by Michael A McDonough in
Google Scholar
PubMed
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Dean Gentle in
Google Scholar
PubMed
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Gail Kirby in
Google Scholar
PubMed
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Susanne Schlisio in
Google Scholar
PubMed
Search for other papers by Rajappa S Kenchappa in
Google Scholar
PubMed
Search for other papers by Bruce D Carter in
Google Scholar
PubMed
Search for other papers by William G Kaelin Jr in
Google Scholar
PubMed
Search for other papers by Peter J Ratcliffe in
Google Scholar
PubMed
Search for other papers by Christopher J Schofield in
Google Scholar
PubMed
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Farida Latif in
Google Scholar
PubMed
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Centre for Rare Diseases and Personalised Medicine, CRUK Renal Molecular Oncology Group, Chemistry Research Laboratory, Howard Hughes Medical Institute, Oxygen Sensing and Cancer Laboratory, Department of Biochemistry and Center for Molecular Neuroscience, Henry Wellcome Building for Molecular Physiology, West Midlands Regional Genetics Service, University of Birmingham, Birmingham B15 2TT, UK
Search for other papers by Eamonn R Maher in
Google Scholar
PubMed
Introduction Germline mutations in the von Hippel–Lindau ( VHL ) tumour suppressor gene and in the B, C and D subunits of succinate dehydrogenase ( SDHB , SDHC and SDHD ) are strongly linked with susceptibility to phaeochromocytoma ( Latif et al
Search for other papers by C D E Margetts in
Google Scholar
PubMed
Search for other papers by D Astuti in
Google Scholar
PubMed
Search for other papers by D C Gentle in
Google Scholar
PubMed
Search for other papers by W N Cooper in
Google Scholar
PubMed
Search for other papers by A Cascon in
Google Scholar
PubMed
Search for other papers by D Catchpoole in
Google Scholar
PubMed
Search for other papers by M Robledo in
Google Scholar
PubMed
Search for other papers by H P H Neumann in
Google Scholar
PubMed
Search for other papers by F Latif in
Google Scholar
PubMed
Search for other papers by E R Maher in
Google Scholar
PubMed
Introduction Phaeochromocytomas are catecholamine-producing tumours that usually arise within the adrenal medulla but are extra-adrenal in 10% of cases. Hypertension is the most consistent clinical feature of phaeochromocytoma and
Search for other papers by Esther Korpershoek in
Google Scholar
PubMed
Departments of Pathology, Neurology, Department of Paediatric Oncology and Haematology, Josephine Nefkens Institute, Erasmus Medical Centre, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Search for other papers by Nanne K Kloosterhof in
Google Scholar
PubMed
Search for other papers by Angelique Ziel-van der Made in
Google Scholar
PubMed
Search for other papers by Hanneke Korsten in
Google Scholar
PubMed
Search for other papers by Lindsey Oudijk in
Google Scholar
PubMed
Search for other papers by Jan Trapman in
Google Scholar
PubMed
Search for other papers by Winand N M Dinjens in
Google Scholar
PubMed
Search for other papers by Ronald R de Krijger in
Google Scholar
PubMed
Introduction In humans, phaeochromocytomas (PCCs) are relatively rare tumours that occur in the adrenal medulla and usually overproduce catecholamines, such as adrenaline or noradrenaline ( Lenders et al . 2005 ). This overproduction causes high
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Georgios Zografos in
Google Scholar
PubMed
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
Division of Translational and Experimental Medicine, University of Warwick Medical School, Clinical Sciences Research Laboratories, Coventry, UK
Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, UK
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
, Lenders et al. 2014 ). Adrenocortical carcinomas (ACCs) account for up to 11% (range 1.2–12%) of adrenocortical tumours, whereas up to 25% of phaeochromocytomas (PCs) may become malignant ( Ayala-Ramirez et al. 2011 , Fassnacht et al. 2016
Search for other papers by Rui M B Maciel in
Google Scholar
PubMed
Search for other papers by Larissa V Bim in
Google Scholar
PubMed
Search for other papers by Cleber P Camacho in
Google Scholar
PubMed
Search for other papers by Janete M Cerutti in
Google Scholar
PubMed
Dear Editor, In a recent issue of Endocrine-Related Cancer , Castinetti et al . reported a different natural history of phaeochromocytoma in multiple endocrine neoplasia type 2 (MEN 2) patients between Europe and South America ( Castinetti
Search for other papers by Emma R Woodward in
Google Scholar
PubMed
Search for other papers by Eamonn R Maher in
Google Scholar
PubMed
Introduction Although the first descriptions of von Hippel-Lindau (VHL) disease were in the 19th century, phaeochromocytoma was first associated with VHL disease only about 50 years ago ( Glushien et al. 1953 ). Traditionally, an
Search for other papers by Umasuthan Srirangalingam in
Google Scholar
PubMed
Search for other papers by Bernard Khoo in
Google Scholar
PubMed
Search for other papers by Lisa Walker in
Google Scholar
PubMed
Search for other papers by Fiona MacDonald in
Google Scholar
PubMed
Search for other papers by Robert H Skelly in
Google Scholar
PubMed
Search for other papers by Emad George in
Google Scholar
PubMed
Search for other papers by David Spooner in
Google Scholar
PubMed
Search for other papers by Linda B Johnston in
Google Scholar
PubMed
Search for other papers by John P Monson in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Search for other papers by W M Drake in
Google Scholar
PubMed
Search for other papers by Scott A Akker in
Google Scholar
PubMed
Search for other papers by Patrick J Pollard in
Google Scholar
PubMed
Search for other papers by Nick Plowman in
Google Scholar
PubMed
Search for other papers by Norbert Avril in
Google Scholar
PubMed
Search for other papers by Daniel M Berney in
Google Scholar
PubMed
Search for other papers by Jacky M Burrin in
Google Scholar
PubMed
Search for other papers by Rodney H Reznek in
Google Scholar
PubMed
Search for other papers by V K Ajith Kumar in
Google Scholar
PubMed
Search for other papers by Eamonn R Maher in
Google Scholar
PubMed
Search for other papers by Shern L Chew in
Google Scholar
PubMed
Introduction Recent studies have shown that ∼25% of apparently sporadic phaeochromocytomas and paragangliomas are due to germ line mutations in one of several familial syndrome genes, including von Hippel-Lindau ( VHL ), RET , succinate
Search for other papers by Joanna Grey in
Google Scholar
PubMed
Search for other papers by Kym Winter in
Google Scholar
PubMed
MEN3). MEN2 predisposes patients to medullary thyroid cancer (99%) and phaeochromocytoma (50%) but also to other conditions according to specific genotype. MEN2A also includes a 25% risk of developing parathyroid hyperplasia and is now recognised as 4